Opthea (ASX:OPT) received a AU$15.9 million research and development tax credit from the Australian Taxation Office, according to a Friday filing with the Australian bourse.
The incentive is for research and development costs incurred in the financial years 2023 to 2024 relating to the development of Opthea's lead product candidate, sozinibercept, the filing stated.
The biopharmaceutical company's shares were down 6% in recent Friday trade.
Price (AUD): $0.66, Change: $-0.04, Percent Change: -5.71%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.